Literature DB >> 34807420

Pathophysiology and Pathogenesis of Marfan Syndrome.

Sanford M Zeigler1, Brandon Sloan1, Jeffrey A Jones2.   

Abstract

Marfan syndrome (MFS) is a systemic connective tissue disorder that is inherited in an autosomal dominant pattern with variable penetrance. While clinically this disease manifests in many different ways, the most life-threatening manifestations are related to cardiovascular complications including mitral valve prolapse, aortic insufficiency, dilatation of the aortic root, and aortic dissection. In the past 30 years, research efforts have not only identified the genetic locus responsible but have begun to elucidate the molecular pathogenesis underlying this disorder, allowing for the development of seemingly rational therapeutic strategies for treating affected individuals. In spite of these advancements, the cardiovascular complications still remain as the most life-threatening clinical manifestations. The present chapter will focus on the pathophysiology and clinical treatment of Marfan syndrome, providing an updated overview of the recent advancements in molecular genetics research and clinical trials, with an emphasis on how this information can focus future efforts toward finding betters ways to detect, diagnose, and treat this devastating condition.
© 2021. Springer Nature Switzerland AG.

Entities:  

Keywords:  Aneurysm; Angiotensin receptor blockers (ARBs); Aorta; Collagen; Endoglin; Extracellular matrix; Extracellular signal related kinase (ERK); Fbn1C1039G/+; Fibrillin; Genetic testing; Ghent nosology; Loeys-Dietz syndrome (LDS); Losartan; Marfan syndrome (MFS); Metalloproteinase; Mitogen-activated protein kinase (MAPK); Mitral valve; SMAD; TGF-β receptor; Thoracic aortic aneurysm and dissection syndrome; Transforming growth factor-β (TGF-β); mgR/mgR; β-Blockers

Mesh:

Substances:

Year:  2021        PMID: 34807420      PMCID: PMC8915437          DOI: 10.1007/978-3-030-80614-9_8

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  104 in total

Review 1.  Fibrillin: from microfibril assembly to biomechanical function.

Authors:  Cay M Kielty; Clair Baldock; David Lee; Matthew J Rock; Jane L Ashworth; C Adrian Shuttleworth
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2002-02-28       Impact factor: 6.237

Review 2.  Making sense of latent TGFbeta activation.

Authors:  Justin P Annes; John S Munger; Daniel B Rifkin
Journal:  J Cell Sci       Date:  2003-01-15       Impact factor: 5.285

3.  Beta-blocker therapy does not alter the rate of aortic root dilation in pediatric patients with Marfan syndrome.

Authors:  Elif Seda Selamet Tierney; Brian Feingold; Beth F Printz; Sang C Park; Dionne Graham; Charles S Kleinman; C Becket Mahnke; Donna M Timchak; William H Neches; Welton M Gersony
Journal:  J Pediatr       Date:  2007-01       Impact factor: 4.406

Review 4.  Update on Clinical Trials of Losartan With and Without β-Blockers to Block Aneurysm Growth in Patients With Marfan Syndrome: A Review.

Authors:  Marion A Hofmann Bowman; Kim A Eagle; Dianna M Milewicz
Journal:  JAMA Cardiol       Date:  2019-07-01       Impact factor: 14.676

5.  Four novel FBN1 mutations: significance for mutant transcript level and EGF-like domain calcium binding in the pathogenesis of Marfan syndrome.

Authors:  H C Dietz; I McIntosh; L Y Sakai; G M Corson; S C Chalberg; R E Pyeritz; C A Francomano
Journal:  Genomics       Date:  1993-08       Impact factor: 5.736

Review 6.  Fine tuning of growth factor signals depends on fibrillin microfibril networks.

Authors:  Noe L Charbonneau; Robert N Ono; Glen M Corson; Douglas R Keene; Lynn Y Sakai
Journal:  Birth Defects Res C Embryo Today       Date:  2004-03

7.  Association of modifiers and other genetic factors explain Marfan syndrome clinical variability.

Authors:  Melodie Aubart; Steven Gazal; Pauline Arnaud; Louise Benarroch; Marie-Sylvie Gross; Julien Buratti; Anne Boland; Vincent Meyer; Habib Zouali; Nadine Hanna; Olivier Milleron; Chantal Stheneur; Thomas Bourgeron; Isabelle Desguerre; Marie-Paule Jacob; Laurent Gouya; Emmanuelle Génin; Jean-François Deleuze; Guillaume Jondeau; Catherine Boileau
Journal:  Eur J Hum Genet       Date:  2018-08-07       Impact factor: 4.246

8.  Abnormal muscle mechanosignaling triggers cardiomyopathy in mice with Marfan syndrome.

Authors:  Jason R Cook; Luca Carta; Ludovic Bénard; Elie R Chemaly; Emily Chiu; Satish K Rao; Thomas G Hampton; Peter Yurchenco; Kevin D Costa; Roger J Hajjar; Francesco Ramirez
Journal:  J Clin Invest       Date:  2014-02-17       Impact factor: 14.808

9.  Meta-analysis Examining the Usefulness of Angiotensin Receptor blockers for the Prevention of Aortic Root Dilation in Patients With the Marfan Syndrome.

Authors:  Abdullah Al-Abcha; Yehia Saleh; Mark Mujer; Manel Boumegouas; Khader Herzallah; Lawrenshey Charles; Layan Elkhatib; Ola Abdelkarim; Michael Kehdi; George S Abela
Journal:  Am J Cardiol       Date:  2020-05-19       Impact factor: 2.778

10.  Noncanonical TGFβ signaling contributes to aortic aneurysm progression in Marfan syndrome mice.

Authors:  Tammy M Holm; Jennifer P Habashi; Jefferson J Doyle; Djahida Bedja; YiChun Chen; Christel van Erp; Mark E Lindsay; David Kim; Florian Schoenhoff; Ronald D Cohn; Bart L Loeys; Craig J Thomas; Samarjit Patnaik; Juan J Marugan; Daniel P Judge; Harry C Dietz
Journal:  Science       Date:  2011-04-15       Impact factor: 47.728

View more
  3 in total

Review 1.  [Latest advances in the diagnosis and treatment of Marfan syndrome].

Authors:  Shu-Ting Yang; Fang Luo
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2022-07-15

2.  Functional Analysis of an Intronic FBN1 Pathogenic Gene Variant in a Family With Marfan Syndrome.

Authors:  Kui Hu; Yun Wan; Fu-Tsuen Lee; Jinmiao Chen; Hao Wang; Haonan Qu; Tao Chen; Wang Lu; Zhenwei Jiang; Lufang Gao; Xiaojuan Ji; Liqun Sun; Daokang Xiang
Journal:  Front Genet       Date:  2022-04-25       Impact factor: 4.772

Review 3.  The complex genetic basis of fibromuscular dysplasia, a systemic arteriopathy associated with multiple forms of cardiovascular disease.

Authors:  Adrien Georges; Nabila Bouatia-Naji
Journal:  Clin Sci (Lond)       Date:  2022-08-31       Impact factor: 6.876

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.